Scott Wolchko | President and CEO |
Dr. Dan Shoemaker | Chief Scientific Officer |
David Nierengarten | Wedbush |
Edward Tenthoff | Piper Jaffray |
Biren Amin | Jefferies |
Daina Graybosch | SVB Leerink |
Nick Abbott | Wells Fargo |
Welcome to the Fate Therapeutics First Quarter 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on Investors & Media section of Fate’s website at fatetherapeutics.com.
As a reminder, today’s call is being recorded. I would now like to introduce Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.